Evidence map›Paper›PMID 41374965›Full record

ReviewCancers2025

Advances in Artificial Intelligence for Glioblastoma Radiotherapy Planning and Treatment.

Reid Master, Nesha Rubin, James Sampson, Kamlesh K Yadav, Shruti Pandita, Aria Sabbagh, Anika Krishnan, Patrick J Silva, Kenneth S Ramos, Vincent Gregoire and 3 more

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Reid MasterSchool of Engineering Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.ORCID 0009-0006-0066-1249
Nesha RubinCenter for Genomics and Precision Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.
James SampsonSchool of Engineering Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.ORCID 0009-0000-1003-9740
Kamlesh K YadavSchool of Engineering Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.
Shruti PanditaICON Clinical Research, 8307 Gault Lane, San Antonio, 78209 TX, USA.
Aria SabbaghVivian L. Smith Department of Neurosurgery, UTHealth Houston, Houston, 77030 TX, USA.ORCID 0000-0001-9000-5099
Anika KrishnanVivian L. Smith Department of Neurosurgery, UTHealth Houston, Houston, 77030 TX, USA.
Patrick J SilvaCenter for Genomics and Precision Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.ORCID 0000-0002-8870-6440
Kenneth S RamosCenter for Genomics and Precision Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.ORCID 0000-0002-0692-4066
Vincent GregoireRadiation Oncology Department, Centre Léon Bérard, 69373 Lyon, France.
Nikos ParagiosCentraleSupélec, University of Paris-Saclay, 91190 Gif-sur-Yvette, France.
Sunil KrishnanVivian L. Smith Department of Neurosurgery, UTHealth Houston, Houston, 77030 TX, USA.ORCID 0000-0002-1340-4771
Tej K PanditaCenter for Genomics and Precision Medicine, Texas A&M Institute of Biosciences and Technology, Houston, 77030 TX, USA.ORCID 0000-0002-2365-5937

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is an aggressive central nervous system tumor characterized by diffuse infiltration. Despite substantial advances in oncology, survival outcomes have shown little improvement over the past three decades. Radiotherapy remains a cornerstone of treatment; however, it faces several challenges, including considerable inter-observer variability in clinical target volume delineation, dose constraints associated with adjacent organs at risk, and the persistently poor prognosis of affected patients. Recent advances in artificial intelligence, particularly deep learning, have shown promise in automating radiation therapy mapping to improve consistency, accuracy, and efficiency. This narrative review explores current auto segmentation frameworks, dose mapping, and biologically informed radiotherapy planning guided by multimodal imaging and mathematical modeling. Studies have demonstrated reproducible tumor segmentations with DSCs exceeding 0.90, reduced planning within minutes, and emerging predictive capabilities for treatment response. Radiogenomic integration has enabled imaging-based classification of critical biomarkers with high accuracy, reinforcing the potential of deep learning models in personalized radiotherapy. Despite these innovations, deployment into clinical practice remains limited, primarily due to insufficient external validation and single-institution training datasets. This review emphasizes the importance of large, annotated imaging datasets, multi-institutional collaboration, and biologically explainable modeling to successfully translate deep learning into glioblastoma radiation planning and longitudinal monitoring.

Indexed as

artificial intelligenceauto segmentationdeep learningdose prediction and mappingglioblastomamachine learningmultimodal imagingpersonalized radiotherapyprecision oncologyradiotherapy planning

Identifiers

PMID41374965
PMCPMC12691521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.